223 related articles for article (PubMed ID: 16916505)
1. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505
[TBL] [Abstract][Full Text] [Related]
2. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
[TBL] [Abstract][Full Text] [Related]
3. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
[TBL] [Abstract][Full Text] [Related]
5. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu gene amplification assessment in breast cancer patients in Isfahan province by real time PCR, differential PCR and immunohistochemistry.
Hojati Z; Orangi E
Gene; 2012 Apr; 497(2):237-42. PubMed ID: 22326523
[TBL] [Abstract][Full Text] [Related]
7. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
Schlemmer BO; Sorensen BS; Overgaard J; Olsen KE; Gjerdrum LM; Nexo E
Scand J Clin Lab Invest; 2004; 64(5):511-22. PubMed ID: 15276916
[TBL] [Abstract][Full Text] [Related]
8. Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections.
Thompson EW; Warton K; Blick T; Wafai R; Hill P; Stanley K
Pathology; 2010 Feb; 42(2):165-72. PubMed ID: 20085519
[TBL] [Abstract][Full Text] [Related]
9. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
10. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
Kim GY; Oh YL
Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
[TBL] [Abstract][Full Text] [Related]
13. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
15. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
[TBL] [Abstract][Full Text] [Related]
16. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
Anttinen J; Kuopio T; Nykanen M; Torkkeli H; Saari U; Juhola M
Anticancer Res; 2003; 23(5b):4213-8. PubMed ID: 14666627
[TBL] [Abstract][Full Text] [Related]
18. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
19. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
